A Double-blind Study Evaluating IPI-504 and Docetaxel in Patients With Non-Small Cell Lung Cancer
Public ClinicalTrials.gov record NCT01362400. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 2, Double-Blind, Placebo-Controlled Study of IPI-504 and Docetaxel in Previously Treated Patients With Stage IIIB or IV Non-Small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to compare the impact of IPI-504 in combination with docetaxel to placebo in combination with docetaxel on life expectancy in patients with Non Small Cell Lung cancer (NSCLC). Docetaxel is an approved chemotherapy for NSCLC. An additional goal of the study is to determine the effect of IPI-504, in combination with docetaxel, verses placebo in, combination with docetaxel, on the growth of cancer
Study identification
- NCT ID
- NCT01362400
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 226 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 30, 2011
- Primary completion
- Feb 28, 2014
- Completion
- Mar 31, 2014
- Last update posted
- May 18, 2014
2011 – 2014
United States locations
- U.S. sites
- 41
- U.S. states
- 20
- U.S. cities
- 41
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Ironwood Cancer and Research Center | Chandler | Arizona | 85224 | — |
| Arizona Oncology Associates | Tucson | Arizona | 85715-4900 | — |
| University of California Irvine Medical Center | Orange | California | 92868 | — |
| PMK Medical Group, Inc. | Oxnard | California | 93030 | — |
| Wilshire Oncology Medical Group, Inc. | Rancho Cucamonga | California | 91730 | — |
| American Institute of Research | Whittier | California | 90603 | — |
| Yale Cancer Center | New Haven | Connecticut | 06519 | — |
| Florida Cancer Specialists | Fort Myers | Florida | 33916 | — |
| Florida Cancer Specialists and Research Institute | St. Petersburg | Florida | 33705 | — |
| Central Indiana Cancer Centers | Carmel | Indiana | 46032 | — |
| Indiana University | Indianapolis | Indiana | 46202 | — |
| Indiana University Health Ball Memorial Hospital | Muncie | Indiana | 47303 | — |
| Community Hospital | Munster | Indiana | 46321 | — |
| Floyd Memorial Cancer Center of Indiana | New Albany | Indiana | 47150 | — |
| Owsley Brown Frazier Cancer Center-Louisville Downtown | Louisville | Kentucky | 40215 | — |
| Tulane University | New Orleans | Louisiana | 70112 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Ann Arbor Hematology Oncology Associates | Ann Arbor | Michigan | 48158 | — |
| Karmanos Cancer Institute | Detroit | Michigan | 48201 | — |
| Sparrow Regional Cancer Center | Lansing | Michigan | 48912 | — |
| Metro Health Cancer Center | Wyoming | Michigan | 49519 | — |
| Southeast Nebraska Cancer Center | Lincoln | Nebraska | 68510 | — |
| Broome Oncology, LLC | Johnson City | New York | 13790 | — |
| Memorial Sloan-Kettering Cancer Center | New York | New York | 14642 | — |
| University of Rochester | Rochester | New York | 14642 | — |
| Blumenthal Cancer Center | Charlotte | North Carolina | 28203 | — |
| Piedmont Hematology Oncology Associates, PLLC | Winston-Salem | North Carolina | 27103 | — |
| Oncology Hematology Care, Inc. | Cincinnati | Ohio | 45242 | — |
| Signal Point Clinical Research Center, LLC | Middletown | Ohio | 45042 | — |
| Willamette Valley Cancer Institute and Research Center | Eugene | Oregon | 97401 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Charleston Hematology Oncology Associates, PA | Charleston | South Carolina | 29414 | — |
| Cancer Centers of the Carolinas | Seneca | South Carolina | 29672 | — |
| Chattanooga Oncology and Hematology Associates, PC | Chattanooga | Tennessee | 37404 | — |
| Sarah Cannon Cancer Center | Nashville | Tennessee | 37203 | — |
| Texas Oncology-Arlington South | Arlington | Texas | 76014 | — |
| Texas Oncology-Baylor Charles A. Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology-Tyler | Tyler | Texas | 75702 | — |
| University of Utah Hospital and Clinics | Salt Lake City | Utah | 84112 | — |
| Virginia Cancer Institute | Richmond | Virginia | 23230 | — |
| Puget Sound Cancer Centers | Edmonds | Washington | 98026 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 24 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01362400, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 18, 2014 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01362400 live on ClinicalTrials.gov.